IXICO CEO Says Milestone Medidata Collaboration Supports Growth Strategy

Why It Matters

The alliance gives IXICO immediate access to Medidata’s extensive client base and infrastructure, accelerating its move into larger, more complex trials while creating recurring revenue, a critical catalyst for scaling in the competitive neuroimaging market.

Key Takeaways

• IXICO partners with Medidata to integrate e‑capture and neuroimaging analytics.
• Collaboration targets larger, more complex clinical trials for biopharma clients.
• Deal aims to generate recurring revenue through volume‑based partnerships.
• IXICO recently secured £1.5 million phase‑two trial extension in the UK.
• New chief commercial officer Tanya Voloshen joins to drive growth.

Summary

IXICO’s chief executive Bram Goorden announced a strategic partnership with Medidata, the multibillion‑dollar leader in electronic data capture and clinical‑trial services. The deal is presented as the first step in IXICO’s “tech‑bio” growth plan, aiming to blend the company’s proprietary neuroimaging analytics with Medidata’s trial‑execution platform.

The collaboration merges Medidata’s e‑capture technology and broad trial‑support infrastructure with IXICO’s state‑of‑the‑art imaging analytics, creating a seamless end‑to‑end solution for biopharma sponsors. Medidata currently serves 18 of the top 25 pharmaceutical companies, 90 % of global CROs, and has supported roughly 38,000 trials across 140 geographies, giving IXICO immediate scale and access to more complex, larger studies.

Goorden emphasized that this is “the first of many” agreements in the tech‑bio space, and highlighted recent commercial wins, including a £1.5 million phase‑two trial extension and the appointment of new chief commercial officer Tanya Voloshen, a Boston‑based industry veteran. These moves underscore a busy quarter and a shift toward recurring, volume‑based revenue streams.

If successful, the partnership could transform IXICO into a one‑stop shop for imaging‑enabled clinical research, broaden its addressable market, and provide a steadier cash flow through long‑term collaborations. The deal also signals a broader industry trend of integrating advanced analytics with trial‑execution platforms to accelerate drug development.

Original Description

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden talked with Proactiv's Stephen Gunnion about the company’s new collaboration with Medidata and how it supports IXICO’s growth strategy in the clinical trials space.

Goorden described the agreement as a significant milestone, highlighting Medidata’s position as “a multibillion dollar player in the clinical trial space” with a global footprint across thousands of trials. The partnership combines Medidata’s electronic data capture and clinical trial technologies with IXICO’s proprietary neuroimaging analytics to create a more seamless solution for biopharma clients.

He explained that the collaboration strengthens IXICO’s ability to scale, giving the company access to larger and more complex clinical trials. Goorden noted that the deal aligns with IXICO’s long-term ambition to expand its presence in high-value studies while enhancing operational reach.

The CEO also pointed to recent commercial momentum, including a £1.5 million contract extension for a global Phase 2 trial and the appointment of a new chief commercial officer, Tanya Voloshen. These developments reflect what he described as “a very busy quarter” for the company.

Looking ahead, Goorden emphasised that the Medidata collaboration represents the beginning of a broader “tech bio strategy,” adding that it is expected to support recurring revenue streams and accelerate growth.

For more insights like this, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel, and enable notifications for future content.

#IXICO #Medidata #ClinicalTrials #Biotech #Neuroimaging

#TechBio #Pharma #HealthcareInnovation #LifeSciences #CEOInterview